🇺🇸 Perfluoropropane in United States

39 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 39

Most-reported reactions

1. Vitreous Haemorrhage — 8 reports (20.51%)
2. Retinal Detachment — 6 reports (15.38%)
3. Endophthalmitis — 5 reports (12.82%)
4. Retinal Haemorrhage — 5 reports (12.82%)
5. Retinal Pigment Epithelial Tear — 5 reports (12.82%)
6. Intraocular Pressure Increased — 3 reports (7.69%)
7. Macular Hole — 2 reports (5.13%)
8. Optic Ischaemic Neuropathy — 2 reports (5.13%)
9. Retinopathy Proliferative — 2 reports (5.13%)
10. Choroidal Neovascularisation — 1 report (2.56%)

Source database →

Frequently asked questions

Is Perfluoropropane approved in United States?

Perfluoropropane does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Perfluoropropane in United States?

National Eye Institute (NEI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.